Back
|
Cell No. : Cell Name
RCB5384 : COLO 320DM#3 SIRT1 KO cl.4 update : 2024/11/11 |
||||
| Comment | ||||
| Comment from the depositor | Human colorectal carcinoma COLO 320DM #3 strain was cloned from the ATCC strain by Von Hoff Laboratory at Texas University around 1990. The strain was used by Shimizu Laboratory at Hiroshima University for development and application of the IR/MAR gene amplification methodology. The strain was further delivered to Mirit I Aladjem Laboratory at US NIH, where the SIRT1 knocked-out clones were isolated. Shimizu Lab in collaboration with Aladjem lab found that the genes amplified in these clones were expressed at very high level. | |||
| Terms and conditions | 1) When publishing research results, the user should cite the literature designated by the depositor (Cancer Res 2001 61(19):6987-90) regarding the IR/MAR gene amplification method. Regarding the increased expression of the amplified gene in the SIRT1 disruptant, please cite the document designated by the depositor (J Biol Chem. 2021 Jan-Jun;296:100356). 2) The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. 3) There is no restriction, if RECIPIENT use the BIOLOGICAL RESOURCE only for publication of research papers. | |||
| Remarks | CRISPR/Cas9 genome edited bioresources Announcement of bioresources developed by the CRISPR/Cas9 technology. | |||
| approver's address |
×
|
|||
| Order Form | Order Form(C-0005.pdf) Approval Form(C-0006.pdf) MTA(C-0065.pdf) | |||
| Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp). | ||||
| Basic information | Depositor | SHIMIZU, Noriaki | ||
| Originator | SHIMIZU, Noriaki | |||
| Year of deposit | 2021 | |||
| Original cell | COLO 320DM | |||
| Cloning (depositor) | Yes | |||
| _Date (depositor) | 2016 | |||
| _Method (depositor) | limiting dilution | |||
| Animal | _human < Mammals | |||
| Genus | Homo | |||
| Species | sapiens | |||
| Race | Caucasian | |||
| Gender | Female | |||
| Age at sampling | 55 years | |||
| Tissue | colon | |||
| Disease name | colorectal carcinoma | |||
| Tumor | neuro-endocrine origin | |||
| Classification | cancer | |||
| Recombinant | recombinant | |||
| Exogene | pCas9-SIRT1 plasmid | |||
| Selection | puromycin | Lifespan | infinite | |
| Morphology | other (rounded and refractile) | |||
| Cellosaurus(Expasy) | CVCL_A6UN | |||
| Medium | Medium List | Culture type | rounded and refractile | Adherent/Suspension cells |
| Culture medium | RPMI 1640 +10%FBS | RPMI1640 + 10% FBS | ||
| Antibiotics | Free | Passage method | pipetting | Culture information | Passage cell No | 3x10 5 cells /ml | 3x10 5 cells /ml |
| SC frequency | once/3-4 days | Subculture : twice/week | ||
| Temperature | 37 ℃ | 37 ℃ | ||
| CO2 concentration | 5 % | 5 % | ||
| Freeze medium | liquid nitrogen :Liquid nitrogenMedium + 10% DMSO, -80℃ : Cell Banker I | Medium + 10% DMSO | ||
| Freezing method | Slow freezing | |||
| Mycoplasma/Acholeplasma | (-) | |||
| Animal PCR | OK | |||
| Saturation density | 2-3x10 6 cells/ml | |||
| Doubling time | 24 hr | |||
| Plating efficiency | 〜80 % | |||
| Others | The cell may form aggregattion. | |||
| STR(human) | OK | |||
| Reference information | Reference | 3 | ||
| User's Publication | 0 | |||
Top
Top
| User's Publication |
Back
CELL BANK Website